Inc. (“BioTime”) is filing this Amendment No. 1 (the “Amendment”) to its Annual Report on Form 10-K for the
period ended December 31, 2017, as originally filed with the Securities and Exchange Commission (the “SEC”) on March
15, 2018 (the “Original Filing”), in accordance with Rule 3-09 of Regulation S-X to include as schedules to this Annual
Report audited financial statements of OncoCyte Corporation (“OncoCyte”) for the year ended December 31, 2017 which
were included in OncoCyte’s Annual Report on Form 10-K filed with the SEC on April 2, 2018 (the “OncoCyte Financial
Statements”). The OncoCyte Financial Statements have been filed an Exhibit to this Amendment and are incorporated by reference
as financial schedules in Item 15 of this Annual Report.
Amendment does not reflect events occurring after the date of the Original Filing or modify or update any disclosures that may
have been affected by subsequent events.